ARTICLE | Clinical News
Azilect rasagiline: Phase III data
September 1, 2008 7:00 AM UTC
In the double-blind, placebo-controlled, international Phase III ADAGIO study, patients who received 1 mg of once-daily Azilect rasagiline for 72 weeks met the 3 primary endpoints based on total UPDRS...